In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in pregnancy. Topics include current recommendations and a discussion of the data to support ART options during pregnancy.
In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Jonah Musa, MBBS, MSCI, PhD
Professor, Obstetrics and Gynecology
University of Jos
Honorary Consultant Obstetrician and Gynecologist
Jos University Teaching Hospital
Jos, Nigeria
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3GRxpGQ
Link to full program:
https://bit.ly/2TXTYWx